BioNTech

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age Pfizer Inc.  and BioNTech SE has announced updated efficacy results from a Phase 2/3 trial evaluating a three 3-µg dose series of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age, reinforcing previously reported […]

Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Read More »

Pfizer

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine

105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses  Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new vaccine supply agreement with the U.S. government to support the continued fight

Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine Read More »